Clinical TrialApr 28, 2026, 07:12 AM
GNPX: Diabetes Gene Therapy GPX-002 Shows Positive Preclinical Data
AI Summary
Genprex, Inc. announced that its research collaborators will present positive preclinical data for its diabetes gene therapy drug candidate, GPX-002 (Pdx1/MafA gene therapy), at the 2026 ASGCT Annual Meeting. The data demonstrated that GPX-002 reversed hyperglycemia in Type 2 diabetic mouse models, significantly improving β-cell function and maturation. The findings suggest the technical translatability of this approach to human application for long-term glycemic control.
Key Highlights
- GNPX's GPX-002 diabetes gene therapy reversed hyperglycemia in Type 2 diabetic mouse models.
- Positive preclinical data will be presented at the 2026 ASGCT Annual Meeting (May 11-15).
- PM treatment improved β-cell function and maturation, increasing mature insulin granules.
- Complete rescue of HFD-induced hyperglycemia was achieved four weeks post-treatment.
- The approach is technically translatable to humans via endoscopic retrograde cholangiopancreatography.
Price Impact
More from GNPX